# ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

> **NCT03911505** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amicus Therapeutics** · enrollment: 21 (actual)

## Conditions studied

- Pompe Disease (Late-onset)

## Interventions

- **BIOLOGICAL:** Cipaglucosidase Alfa
- **DRUG:** Miglustat

## Key facts

- **NCT ID:** NCT03911505
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-13
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911505, "ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03911505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*